• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » AstraZeneca, Repositive partner on oncology research consortium

AstraZeneca, Repositive partner on oncology research consortium

August 15, 2016
CenterWatch Staff

Repositive, a software company developing novel tools to improve access to human genomic research data, is launching a consortium project in collaboration with AstraZeneca to develop a collaborative, pre-competitive resource to provide streamlined discovery and access to molecular data from Patient Derived Xenografts (PDXs) for use within oncology research. 

The consortium project was inspired by an idea submitted to the Pistoia Alliance, via their IP3 platform a global, not-for-profit alliance of life science companies, vendors, publishers, and academic groups dedicated to improving global life sciences research and development. Repositive and AstraZeneca are inviting Pistoia Alliance members and other interested organizations to join the collaborative project as partners in developing the pre-competitive PDX resource. 

Patient Derived Xenografts (PDXs) are derived by direct implantation of cancerous tissue from a patient into an immunodeficient mouse. They harbor advantages over cancer cell line derived xenografts since the tumors have not been exposed to the selective pressures, stimuli, damage and genetic evolution resulting from the cell culturing process. As a result PDX’s better maintain the heterogeneity and structure of the original patient tumor, and therefore experimental results and drug responses are more directly translatable to the clinic.

The consortium will use the Repositive platform, a purpose built platform to improve access to human genomic data, alongside AstraZeneca’s knowledge and expertise in oncology. The consortium is looking for additional industrial and academic partners to provide improved data and develop new tools for use in improving oncology research.

Fiona Nielsen, CEO of Repositive, said, “We are happy to apply the Repositive skills in data sourcing and web application development to such immediate beneficial effects to the consortium partners. Users of the Repositive platform can quickly and easily access human genomic data from a wide range of sources, making it ideal for improving data discovery and access.”

PDX consortium partners will benefit from early access to the resource and tools as they are being developed, and the features and data availability on the resource will be prioritized according to the needs of the consortium members. Opportunities to extend the resource to immuno-competent tumor models can also be explored.

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • TechInnovation-360x240.png

    Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

  • AskTheExperts-360x240.png

    Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing